EARLY BLACK FRIDAY: 40% OFF orders above $150 - use code BF40

Compare
Home/Compare

Every cannabinoid pair, side by side.

There are over a hundred cannabinoids in cannabis and around ten of them are sold to consumers. They act at different receptors, in different directions, and their evidence bases differ enormously, from three regulatory-grade trials at one end to zero human studies at the other.

FDA structure and function languageNo disease claims
100% OrganicThird Party Tested30-Day Money Back GuaranteeHighest QualityFull SpectrumGlobal Shipping
100% OrganicThird Party Tested30-Day Money Back GuaranteeHighest QualityFull SpectrumGlobal Shipping

What actually separates these compounds.

Three things separate these compounds, and none of them is a flavour preference. Read them before you read any comparison, because they decide what a claim is worth.

Different receptors

CBD does not activate CB1 at all. THC is a partial agonist at it. CBC prefers CB2. The target decides the effect.

Different directions

Two cannabinoids can meet the same receptor and pull opposite ways. THCV blocks CB1 at low doses and activates it at high ones.

Different evidence

From three regulatory-grade trials at one end to zero human studies at the other. Most minor cannabinoid data is in vitro or rodent.

Start with the question you actually have.

Most comparison content treats cannabinoids as a menu of wellness options. They are not that. They act at different receptors, in different directions, and their evidence bases differ enormously.

Lion’s Mane vs Reishi
Lion's mane is Hericium erinaceus. Reishi is labeled Ganoderma lucidum but cultivated lingzhi is Ganoderma sichuanense. Only one has positive trials.
Read comparison →
Lion’s Mane vs Cordyceps
Lion's mane is Hericium erinaceus. Cordyceps in a capsule is almost always Cordyceps militaris or the Cs-4 ferment, not the wild caterpillar fungus.
Read comparison →
Lion’s Mane vs Reishi vs Cordyceps
One species is certain, one is misnamed, one is a genus. Lion's mane, reishi and cordyceps compared on compounds, extraction and human trial evidence.
Read comparison →
Reishi vs Chaga
Reishi is the fruiting body of Ganoderma lucidum with two active fractions. Chaga is the sterile conk of Inonotus obliquus and is high in oxalate.
Read comparison →
Cordyceps vs Reishi
Cordyceps names at least two fungi, marked by cordycepin or adenosine. Reishi is one species, measured by beta-glucans and ganoderic acid triterpenes.
Read comparison →
Chaga vs Turkey Tail
Chaga is a sterile conk high in oxalate with no human trials at all. Turkey tail's trial record belongs to PSK, a licensed Japanese preparation.
Read comparison →
Turkey Tail vs Reishi
Turkey tail is Trametes versicolor, reishi is Ganoderma lucidum. Their human trial records differ sharply, and neither one was run on a retail extract.
Read comparison →
Maitake vs Shiitake
Maitake is Grifola frondosa and shiitake is Lentinula edodes. Both are foods first, and one of them causes a documented rash when undercooked.
Read comparison →
Lion’s Mane vs Ashwagandha
Lion's mane is a fungus, ashwagandha a nightshade root with a documented liver injury signal and a ban in Denmark. They are not comparable products.
Read comparison →
Reishi vs Ashwagandha
A fungus and a nightshade root, both sold for calm. Both have published liver case reports, but only one has been prohibited in a national market.
Read comparison →
Full Spectrum vs Broad Spectrum vs Isolate
Full spectrum keeps the plant's THC, broad spectrum removes it, isolate is 99 percent CBD. What each contains, and what the trials actually show.
Read comparison →
CBD Isolate vs Distillate
CBD isolate is 99 percent pure cannabidiol; distillate is a 70 to 90 percent cannabinoid cut. What each retains, and why neither has a human trial.
Read comparison →

No comparison matches that search.

The honest summary.

Every claim on this table is sourced on the individual pages. Binding affinity numbers for the minor cannabinoids are genuinely inconsistent between labs, so assay context matters.

Compound
CB1 receptor
CB2 receptor
Other target
Human evidence
Intoxicating
Where it comes from
CBD
No activation. Negative allosteric modulator
Ki 240 nM, low efficacy
ENT1 transporter under 250 nM; TRPA1 ~0.09 μM
Strong in rare epilepsy, negative in pain
No
CBDA, decarboxylated
THC
Partial agonist, Ki 20 to 36 nM
Ki 31 to 52 nM
TRPA1, 0.23 μM
Extensive, including approved medicines
Yes
THCA, decarboxylated
CBG
Weak, Ki around 1.3 μM
Weak partial, Ki 490 nM
Alpha-2 adrenoceptor, EC50 0.2 nM
One human trial
No
CBGA, the parent precursor
CBN
Weak partial, 29 percent max effect
Negligible
TRPA1, 0.18 μM
One polysomnography trial
Weakly, very high doses
Oxidation of THC
CBC
Disputed between studies
CB2-preferring, Ki 27 nM
TRPA1, approximately 0.09 μM
None
No
CBCA, decarboxylated
CBDa
Inactive, Ki above 10 μM
Low efficacy
COX-2, EC50 2 μM, 9-fold selective
No controlled trials
No
Native plant product
CBDV
Inactive
Ki 140 nM, EC50 5.0 nM
TRPA1, 0.42 μM
Two designed trials, both negative
No
CBDVA, propyl series
THCV
Antagonist at low dose, agonist at high
Partial agonist, Ki 47 to 63 nM
5-HT1A positive modulation
Limited early-stage work
Dose-dependent
THCVA, propyl series
THCa
Weak, EC50 above 10 μM
Disputed
PPAR-gamma, potent
Essentially none in humans
No, until heated
Native plant product
Delta-8 THC
Partial agonist, Ki around 36 nM
Around 50 nM, same as delta-9
Same profile as delta-9
Minimal; EFSA equates potency to delta-9
Yes
Acid conversion, usually from CBD
Showing 6 of 10 compounds

Important context: Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg. No trial evidence supports scaling those findings down.

Eight cannabinoids, eight evidence bases.

Receptor figures are in vitro and vary between laboratories. The evidence bar counts human trials, not cell studies.

CBDNon-intoxicating
Cannabidiol
CB1No activation
CB2Ki 240 nM
OriginCBDA, decarboxylated
Human evidenceDozens of trials
THCIntoxicating
Delta-9-tetrahydrocannabinol
CB1Partial agonist, 20 to 36 nM
CB2Ki 31 to 52 nM
OriginTHCA, decarboxylated
Human evidenceExtensive
CBGNon-intoxicating
Cannabigerol
CB1Weak, Ki 1.3 μM
CB2Weak partial, 490 nM
OriginCBGA, the precursor
Human evidenceOne trial
CBNIntoxicating
Cannabinol
CB1Weak partial, 29 percent
CB2Negligible
OriginOxidation of THC
Human evidenceOne sleep trial
CBCNon-intoxicating
Cannabichromene
CB1Disputed
CB2CB2-preferring, 27 nM
OriginCBCA, decarboxylated
Human evidenceNone
CBDaNon-intoxicating
Cannabidiolic acid
CB1Inactive above 10 μM
CB2Ki 12 nM, low efficacy
OriginNative plant product
Human evidenceNone controlled
CBDVNon-intoxicating
Cannabidivarin
CB1Inactive
CB2Ki 140 nM
OriginCBDVA, propyl series
Human evidenceTwo, both negative
THCVIntoxicating
Tetrahydrocannabivarin
CB1Antagonist low, agonist high
CB2Partial, 47 to 63 nM
OriginTHCVA, propyl series
Human evidenceLimited

One precursor. Several directions.

Understanding the biosynthesis makes the table easier to read. Cannabis makes one precursor, CBGA. Three enzymes compete for it. THCA synthase produces THCA. CBDA synthase produces CBDA. CBCA synthase produces CBCA. Whatever CBGA is left becomes CBG.

Heat and time then strip a carbon dioxide group from each acid, giving THC, CBD, CBC and CBG.

One precursor. Several directions.
Two compounds sit outside that scheme

CBN has no synthase; it is what THC becomes when it oxidises. Delta-8 THC is barely present in natural hemp and is generally manufactured by acid conversion from CBD.

And a separate branch makes the varins

Built from a shorter starting molecule, it produces CBDV and THCV. That branch is genetically segregated, which is why varin content is rare in ordinary hemp.

Three things worth knowing first.

Each one changes what a claim on the pages ahead is actually worth.

Three things worth knowing first.
01
The dose gap

Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg. No trial evidence supports scaling those findings down.

02
Most minor cannabinoid data is preclinical

CBC, CBDa and THCa have essentially no controlled human data at all. Binding affinity numbers are also genuinely inconsistent between labs, and any single figure quoted without its assay context is misleading.

03
The entourage effect is not established

Two studies designed specifically to test whether cannabis terpenes modulate cannabinoid receptor activity found they do not. A 2024 scoping review concluded there is limited evidence for it as a stable and predictable phenomenon.

Why we publish the numbers, not the claims.

Explore Endoca

We grow our own hemp, run our own extraction and publish a third-party certificate of analysis for every batch, so we can tell you the measured cannabinoid content tied to the batch code on the bottle.

A company selling these compounds has an obvious incentive to overstate them. We would rather publish the trials that failed alongside the ones that worked.

01
Our own fieldsOrganically grown hemp, cultivated by us rather than bought in.
02
Our own extractionCO2 extraction in our own labs, so the process is ours end to end.
03
A COA per batchMeasured cannabinoid content published against the code on your bottle.
04
Negative results tooWe publish the trials that failed alongside the ones that worked.

References

Each comparison page carries its own reference list. These are the primary sources underpinning the master table.

01Zagzoog A et al. In vitro and in vivo pharmacological activity of minor phytocannabinoids. Sci Rep 2020;10:20405.
02Walsh KB, McKinney AE, Holmes AE. Minor Cannabinoids. Front Pharmacol 2021;12:777804.
03De Petrocellis L et al. Effects of cannabinoids on TRP channels. Br J Pharmacol 2011;163:1479-1494.
04Pertwee RG. Br J Pharmacol 2008;153:199-215.
05Ibeas Bih C et al. Molecular Targets of Cannabidiol. Neurotherapeutics 2015;12:699-730.
06EFSA CONTAM Panel. EFSA Journal 2025;23(11):e9735.
07Congressional Research Service. Legal Sidebar LSB11381, 22 December 2025.